RVA Reva Medical Inc

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and CEO, Robert Stockman, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. US PST on Wednesday, January 11, 2012. The conference is being held January 9 through 12, 2012 at The Westin St. Francis Hotel in San Francisco, California.

A copy of the presentation materials will be available on REVA's website at www.revamedical.com shortly before the presentation.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA's lead product, the ReZolve™ scaffold, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold. The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

CONTACT: United States
         
         Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         +1 858 966-3045
         
         Australia
         
         Investor Enquiries:
         David Allen or Alan Taylor
         Inteq Limited
         +61 2 9231 3322
         
         Media Enquiries:
         Katie Mackenzie or Rebecca Wilson
         Buchan Consulting
         +61 3 9866 4722